Jin, Junfei <br/><br/>
Bcl-2 and Bcl-xL mediate resistance to receptor tyrosine kinase-targeted therapy in lung and gastric cancer.  [electronic resource] 

 -  Anti-cancer drugs  11 2017 
 - 1141-1149 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1473-5741 
<br/><br/><label>Standard No.: </label>10.1097/CAD.0000000000000561  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aniline Compounds--administration & dosage<br/>Animals<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Cell Line, Tumor<br/>Drug Resistance, Neoplasm<br/>Drug Synergism<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>MAP Kinase Signaling System--drug effects<br/>Male<br/>Mice<br/>Mice, Nude<br/>Molecular Targeted Therapy<br/>Phosphoinositide-3 Kinase Inhibitors<br/>Protein Kinase Inhibitors--administration & dosage<br/>Proto-Oncogene Proteins c-akt--antagonists & inhibitors<br/>Proto-Oncogene Proteins c-bcl-2--antagonists & inhibitors<br/>Random Allocation<br/>Stomach Neoplasms--drug therapy<br/>Sulfonamides--administration & dosage<br/>Up-Regulation<br/>Xenograft Model Antitumor Assays<br/>bcl-X Protein--antagonists & inhibitors